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Abstract: OBJECTIVE: To determine the effect of a linear gadolinium-based contrast agent (GBCA)
on the signal intensity (SI) of the deep cerebellar nuclei (DCN) in a retrospective clinical study on dogs
after multiple magnetic resonance (MR) examinations with intravenous injections of gadodiamide and
LA-ICP-MS analysis of a canine cerebellum after gadodiamide administration. ANIMALS: 15 client-
owned dogs of different breeds and additionally 1 research beagle dog cadaver. PROCEDURES: In the
retrospective study part, 15 dogs who underwent multiple consecutive MR imaging examinations with
intravenous injection of linear GBCA gadodiamide were analyzed. SI ratio differences on unenhanced
T1-weighted MR images before and after gadodiamide injections was calculated by subtracting SI ratios
between DCN and pons of the first examination from the ratio of the last examination. Additionally,
1 research beagle dog cadaver was used for LA-ICP-MS (Laser ablation inductively coupled plasma
mass spectrometry) analysis of gadolinium in the cerebellum as an add-on to another animal study.
Descriptive and non-parametrical statistical analysis was performed and a p-value of < 0.05 was considered
significant. RESULTS: No statistically significant differences of SI ratios, between DCN and pons, were
detectable based on unenhanced T1-weighted MR images. LA-ICP-MS analyses showed between 1.5 to
2.5 ฀g gadolinium/g tissue in the cerebellum of the examined dog, 35 months after the last of 3 MRI
examination with gadodiamide (two examinations at a dose of 1 x 0.1mmol/kg, last examination at a
dose of 3 x 0.05mmol/kg). CONCLUSION AND CLINICAL RELEVANCE: Although the retrospective
MRI study did not indicate any visible effect of SI increase after multiple gadodiamide exposures, further
studies based on LA-ICP-MS showed that the optical threshold was not reached for a potential visible
effect. Gadolinium was detectable at a level of 1.5 to 2.5 ฀g gadolinium/g tissue by using LA-ICP-MS in
the cerebellum 35 months after last MRI examination. The general importance of gadolinium retention
of subvisible contents requires further investigation.
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To determine the effect of a linear gadolinium-based contrast agent (GBCA) on the signal
intensity (SI) of the deep cerebellar nuclei (DCN) in a retrospective clinical study on dogs
after multiple magnetic resonance (MR) examinations with intravenous injections of gado-
diamide and LA-ICP-MS analysis of a canine cerebellum after gadodiamide administration.
Animals
15 client-owned dogs of different breeds and additionally 1 research beagle dog cadaver.
Procedures
In the retrospective study part, 15 dogs who underwent multiple consecutive MR imaging
examinations with intravenous injection of linear GBCA gadodiamide were analyzed. SI
ratio differences on unenhanced T1-weighted MR images before and after gadodiamide
injections was calculated by subtracting SI ratios between DCN and pons of the first exami-
nation from the ratio of the last examination. Additionally, 1 research beagle dog cadaver
was used for LA-ICP-MS (Laser ablation inductively coupled plasma mass spectrometry)
analysis of gadolinium in the cerebellum as an add-on to another animal study. Descriptive
and non-parametrical statistical analysis was performed and a p-value of < 0.05 was consid-
ered significant.
Results
No statistically significant differences of SI ratios, between DCN and pons, were detectable
based on unenhanced T1-weighted MR images. LA-ICP-MS analyses showed between 1.5
to 2.5 μg gadolinium/g tissue in the cerebellum of the examined dog, 35 months after the
last of 3 MRI examination with gadodiamide (two examinations at a dose of 1 x 0.1mmol/kg,
last examination at a dose of 3 x 0.05mmol/kg).
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Conclusion and clinical relevance
Although the retrospective MRI study did not indicate any visible effect of SI increase after
multiple gadodiamide exposures, further studies based on LA-ICP-MS showed that the opti-
cal threshold was not reached for a potential visible effect. Gadolinium was detectable at a
level of 1.5 to 2.5 μg gadolinium/g tissue by using LA-ICP-MS in the cerebellum 35 months
after last MRI examination. The general importance of gadolinium retention of subvisible
contents requires further investigation.
Introduction
In 2014 Tomori Kanda[1] published his work about signal intensity (SI) increase on unen-
hanced T1 weighted magnetic resonance imaging (MRI), causing hyperintensities in the den-
tate nucleus (DN)-to pons and globus pallidus to thalamus after consecutive injections of
gadolinium-based contrast agents (GBCAs). His important work was the beginning of an
ongoing debate about the deposition of GBCAs in patient’s brains.[1–18] It is shown in
numerous studies on humans and in a few animal studies that there is a positive correlation
between SI increase on unenhanced T1 weighted MRI and the gadolinium concentration in
the brain.[19–25] Currently, the scientific interest focuses on the question whether all GBCAs
or only a specific GBCA subtype is causing such hyperintensities. As free ionic gadolinium is
toxic, GBCAs are applied as chelates. According to their chemical structure, two subtypes of
GBCAs can be classified. GBCAs of the linear subtype partially and GBCAs of the macrocyclic
subtype completely enclose gadolinium. On the one hand, the majority of studies provided evi-
dence that linear GCBAs are stronger correlated with SI increase in the DN.[1, 3–7, 13–15, 17,
18, 20, 22–24, 26–43] On the other hand, SI increase was described after macrocyclic GBCA
administration in a few studies that were controversial discussed between specialists due to
their limitations.[3, 5, 7, 8, 17] It seems that the molecular structure of the GBCA ligand,
which defines the GBCA subtype, is a crucial factor for the SI increase on unenhanced T1
weighted MRI.[44]
In 2017, as a consequence of the scientific debate, regulatory authorities (EMA, European
Medicine Agency; FDA Food and Drug Administration) decided about safety issues using
GBCAs during clinical work-up, which resulted in divergent actions between EU and USA.
[25] Based on a precautionary approach in the European Union nearly all linear GBCAs were
removed from the market, while the FDA issued a class warning for all GBCAs.
Until now, the majority of published animal studies about this topic were performed on
rodents[23, 24, 45–49] the minority on large experimental animals.[25] So far, in veterinary
medicine, no studies described a potential SI increase after multiple linear GBCA administra-
tions in client-owned dogs. This species is of special clinical interest, as dogs will potentially
face multiple MR examinations in veterinary medicine during treatment of tumors or during
neurological diseases. Moreover, dogs play an indispensable role as animal model for transla-
tional research approaches. Therefore, the question arises if in dogs, similar to humans, an SI
increase in the DCN is detectable after consecutive MR examinations or whether the number
of GBCA administration is below the limit of detection for a visible SI increase on unenhanced
T1-weighted MR images. This study followed the guidelines for standardized assessment of SI
increase for retrospective MRI studies published from the European Gadolinium Retention
Evaluation Consortium (GREC).[44]
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In the current study, we aimed to retrospectively assess clinical data of dogs after multiple
MRI examinations with intravenous administration of gadodiamide. Additionally, the brain of
one dog, which was euthanized unrelated to this study, underwent an LA-ICP-MS measure-
ment of gadodiamide 35 months after last MRI examination.[50–52] We hypothesized that
there is an increased hyperintensity on non-enhanced T1 weighted sequences in the deep cere-
bellar nucleus (DCN) of dogs after multiple gadodiamide administrations and a detectable
gadodiamide retention in the cerebellum of dogs with LA-ICP-MS.
Material andmethods
Dataset of patients
This restrospective study was performed onMR imaging data sets of 18 client-owned dogs pre-
sented between August 2012 and October 2017 at the Clinic for Diagnostic Imaging at the Vet-
suisse Faculty of the University of Zurich. Inclusion criteria was that the dogs had multiple
(defined as two or more) MR examinations of the brain with intravenous administration of
the linear GBCA gadodiamide at a dose of 0.15mmol/kg. Three patients did not undergo
unenhanced T1-weighted imaging or were unreadable for study purposes and were excluded
from this study. However, 15 client-owned dogs met the inclusion criteria and had a history of
neoplastic or neurological disease as reason for MRI examination. Demographic and clinical
characteristics of the all animals in the dataset is summarized in Table 1. All animals under-
went general anesthesia during MRI examination based on a standard anesthesia protocol.
After premedication with butorphanol and continious intravenous lactated Ringer’s infusion,
general anesthesia was induced with propofol and maintained with isoflurane combined in
oxygen and air. One research beagle dog cadaver, which was euthanized unrelated to this
study, was used for dissection and sampling of the whole brain. Accordingly, the additional
organ sampling, which was an add-on to the main study purpose, applied 3R requirements
and maximized the scientific output from the dog. LA-ICP-MS was used for determination of
Gd-concentration in the cerebellum.
Imaging and data analysis
The analysis included whole-brain MR imaging obtained between 2016 and 2019 at the Vet-
suisse Faculty Zurich. Imaging was performed with a 3.0-T MRI (Philips Ingenia, Philips Neth-
erlands). Transverse unenhanced T1-weighted image parameters were as follows: Repetition
time: 11.15–13.17 ms, Echo time: 5.116–6.125 ms, slice thickness: 0.7 mm, number of averages:
1, acquisition matrix: 0/228/227/0 and echo train length: 227.
Image analysis was performed independently by two of the authors (HR, PK). A picture
archiving and communication system (Synapse1 PACS, Fujifilm) was used for all reading ses-
sions. Evaluation of the images, including analysis of ROIs and the mean SI values, was per-
formed with open source medical image viewer (Horos based upon OsiriXTM, 64-bit medical
image viewer for OS X, Version 3 (LGPL-3.0)). Pre- and postcontrast images were subjectively
compared and analyzed regarding presence of signal alteration in the region of the deep cere-
bellar nuclei (DCN). Regions of interest (ROI) were drawn on the unenhanced T1-weighted
images on the central pons, and the DCN on both hemispheres. (Fig 1) The anatomically cor-
rect description of the DN in dogs is Nucleus lateralis cerebelli, which is the most prominent
DCN. Accordingly, we use the more generalized term DCN instead of DN or Nucleus lateralis
cerebelli to better reflect the canine anatomical situation. The correct placement of the ROI
was confirmed by using T2-weighted images at the same section position for identification of
the DCN in unclear cases. The DCN-to-pons SI ratio was calculated by using the following
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formula:
DCN to pons SI ratio ¼ ðmean SI of DCNÞ=ðmean SI of central ponsÞ:
The first and last MR examination of the dogs was used to calculate the SI ratio difference
by substracting the first examination SI ratio from the last examination SI ratio.
Cadaver sample preparation
The research beagle dog was euthananized according to another unrelated study (animal
license number ZH057/17) in accordance to Swiss animal welfare act. As an add-on to the
main study, the dog’s brain was harvested directly after euthanasia. The left brain hemisphere
was coronally cut into 0.5–1.0 cm slices and cryopreserved (at −80˚C). Deep cerebellar nuclei
of the left cerebellum were cut into a 50-μm-thick section and fixed on a piece of cork with Tis-
sue-Tek O.C.T. Compound (Sakura Finetek GmbH, Staufen, Germany). For chemical analysis,







time between last GBCA and
last MRI [days]
gender breed type of disease
1 11.2 2 3.36 254 female,
neutered
Spitz meningioma
2 33.0 2 9.90 169 male Labrador Retriever meningioma
3 37.0 3 16.65 98 male Boxer unspecified recurrent brain
tumor
4 15.5 2 4.65 77 male,
neutered
franz. Bulldogge pituitary tumor
5 24.6 2 7.38 92 female,
neutered
Magyar Vizsla meningioma
6 6.0 2 1.80 137 female,
neutered
Jack Russel Terrier meningioma
7 13.2 2 3.96 582 male,
neutered
franz. Bulldogge cushing
8 1.8 2 0.54 138 male Yorkshire Terrier meningoencephalitis





10 29.0 2 8.70 24 male Boxer unspecified recurrent brain
tumor
11 29.5 2 8.85 114 male,
neutered
Collie meningioma
12 22.7 2 6.81 374 male,
neutered
Labrador Retriever meningioma
13 35.5 2 10.65 135 male Boxer unspecified recurrent brain
tumor
14 8.5 2 2.55 217 male,
neutered
Jack Russel Terrier pituitary tumor
15 22.4 3 10.08 106 female,
neutered
Labrador Retriever pituitary tumor
16 11.4 3 5.13 552 female beagle healthy
median 22.6 2 6.83 136
min 1.8 2 0.54 24
max 37.0 3 16.65 582
Demographic and clinical characteristics of all dogs displayed with date of birth (DOB), age at last MRI [months], bodyweight (BW) [kg], number of GBCA
applications, cumulated dose [mmol/animal], time between last GBCA and last MRI [days], gender, breed, and type of disease.
https://doi.org/10.1371/journal.pone.0227649.t001
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the deep cerebellar nuclei were cut in thin sections of 10-μm thickness with a cryotome and
mounted on microscopic glass slides. Before the ablation process, microscopic images were
recorded with a BZ-9000 inverted fluorescence/bright field microscope (Keyence, Osaka,
Japan). The right hemisphere of the brain was formalin fixed (4% buffered formalin), paraffin
embedded, and stored until further analysis.
Localisation of deep cerebral nuclei by bench-top μXRF
For the localisation of deep cerebral nuclei, an M4 Tornado bench-top μXRFinstrument (Bru-
ker Nano GmbH, Berlin, Germany) was used. The rhodium X-ray tube was supplied with a
voltage of 50 kV and a current of 600 μA throughout the measurements. The emitted X-ray
fluorescence was detected by a silicon drift detector (XFlash1 5030, Bruker Nano GmbH, Ber-
lin, Germany). Spatial resolution was approximately 25 μm. Each pixel was measured twice for
200 ms at a pressure of 20 mbar. The data was evaluated using the software ESPRIT HyperMap
(Bruker Nano GmbH, Berlin, Germany).
Standard preparation for LA-ICP-MS
For calibration, 11 matrix-matched gelatine standards in a concentration range from 0 ng/g to
600 μg/g were created. For this purpose, a 1000 μg/g gadolinium (Gd) ICP-MS standard
(Fluka Analytical, St. Gallen, Switzerland) was diluted and combined with gelatine of highest
purity (Grüssing GmbH, Filsum, Germany) resulting in standards with a gelatine content of
10% (w/w). The suspension was homogenized by heating the standards to a temperature of
50˚C and the usage of a vortex mixer. Afterwards, 10 μm thin slices of each standard were pre-
pared via a CryoStar NX70 Cryostat (Thermo Fisher Scientific, Waltham, USA). The thin slices
of the standards where then mounted onto a microscopic slide.
The Gd concentration in the gelatine standards was confirmed by ICP-TQMS (iCAP TQ,
Thermo Fisher Scientific, Waltham, USA) analysis of the digested standards. For digestion,
500 μL concentrated nitric acid (Merck Chemicals GmbH, Darmstadt, Germany) and 100 μL
Fig 1. T1 weighted unenhanced images a dogs brain in transversal orientation at the level of DCN; Colored circles indicate ROI at the Pons (proximal circles) and DCN
(distal circles) in the left and right hemisphere A: first examination precontrast, B: second examination precontrast 105 days after first examination; related SI
measurements of the ROIs showing measured area in mm2, Mean, Min, Max and SD of SI in the ROI.
https://doi.org/10.1371/journal.pone.0227649.g001
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35% (w/w) hydrogen peroxide (Acros Organics, Geel, Belgium) were added to around 50 mg
of each gelatine standard. The mixture was then heated to a temperature of 70˚C until com-
plete digestion. Afterwards, the digests were diluted and a rhodium (Rh) ICP-MS standard
(SCP Science, Baie-D’Urfe, Canada) was added as an internal standard. The concentration was
determined using an external Gd calibration in a range from 0 pg/g to 30 ng/g consisting of 12
standards. Again, Rh was used as an internal standard.
LA-ICP-MSmeasurements
For elemental mapping of the Gd distribution, the hyphenation of an LSX 213 G2+ (Cetac
Technologies, Omaha, USA) laser ablation system equipped with a HelEx II cell (Teledyne
Cetac Technologies, Omaha USA) and an ICP-MS 2030 (Shimadzu, Kyoto, Japan) was used.
For ablation, a spot size of 10 μm in combination with a stage speed of 30 μm/s was chosen.
Laser energy was optimized for each individual sample to allow for quantitative ablation of the
sample with minor ablation of the object slide. Ablated particles were washed out by a constant
helium flow of 800 mL/min. For more efficient transportation, a daily tuned argon flow was
added on the line to the micro torch of the ICP-MS system. A wet argon plasma with an RF
power of 1200 W was used for the ionisation. The ionized analytes were led through a nickel
interface and were analysed by an SQ-KED setup.
For quantification, the previously described matrix-matched Gd gelatine standards were
used. On each standard, 11 lines with an ablation time of 20 s per line were ablated with the
same parameters as used for the sample. The first line of each recording was discarded for con-
sistency reasons.
All data evaluation was performed using the software ImaJar (developed by Robin Schmid,
Muenster, Germany).
Statistics
Statistical data was analyzed by using SPSS (IBM1 SPSS1 Statistics, version 25, 64-bit-version,
IBM, Chicago, Ill). Due to the limited number of available cases, data was defined as non-nor-
mally distributed and quantitative data was presented with median (range). Non-parametrical
tests were used to compare SI ratio differences between 2 independent observers (Mann-Whit-
ney U test). Inter-rater reliability was assessed based on Intraclass-Correlation-Coefficient
(ICC) in a range from 0.0 to 1.0, whereby large numbers mean better reliability. One-sample t-
tests were used to examine if the mean SI ratio differences between first and last examination
were different from 0. A p-value of< 0.05 was considered significant.
Results
Cinical and demographic aspects
An overview about the demographic and cinical characteristic of the dataset is available pro-
vided as Table 1. The mean age of all dog patients included was 96.20 (31–157) months. The
animals gender was divided as followed: male (5), male castrated (5), female castrated (5). As
this was a restrospective clinical study, the dogs were of different breeds: Boxer (3), Border
Collie (1), French Bulldog (2), Jack Russel Terrier (2), Catalan Scheepdog (1), Labrador
Retriever (3), Magyar Vizsna (1), Spitz (1), Yorkshire Terrier (1). Contrast media injection
protocols were the same for all animals, as they followed a clinical standard operation proce-
dure with 0.15 mmol/kg gadodiamide for each MRI examination. The time between the MRI
examinations was caused by the clinical work-up and was in median 136 (24–582) days.
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Additionally, one research beagle dog cadaver was included into this study, which was
euthanized for another unrelated study. The research beagle dog was used for different studies
including repetitive gadodiamide administrations in MRI before his termination. It was a 52
months old, female castrated beagle dog with 11.4 kg body weight. The contrast media injec-
tions of the dog were as followed: November 2013 (0.1 mmol/kg gadodiamide), December
2013 (0.1 mmol/kg gadodiamide), June 2015 (3 x 0.05 mmol/kg gadodiamide). Accordingly,
the last gadodiamide injection was 35 months before termination. Following the 3R require-
ments, the brain of the dog was sampled and used for chemical analysis, as this was not possi-
ble to perform with the retrospectively examined clinical patient population.
MRI data
Unenhanced T1-weighted imaging were independenly analyzed by two observers (HR, PK). A
summary of all measurements are provided as Table 2. SI values of the DCN and Pons as well
as the SI ratios and the SI ratio differences between the first and the last examination of the left
and right hemisphere are summarized in Table 3. Based on non-parametric Mann-Whitney U
tests, no significant differences were detectable between both observers at a significance level
of p< 0.05 (SI DCN left (p = 0.988), SI Pons left (p = 0.882), SI ratio left (p = 0.329), SI DCN
right (p = 0.976), SI Pons right (p = 0.894), Si ratio right (p = 0.605), SI ratio difference left
(p = 0.756), SI ratio difference right (p = 0.548).
The ICC showed very good agreement between both observers (Table 3). For all analyses,
ICC was between 0.863 (SI ratio difference right hemisphere)– 0.999 (SI DCN left, SI Pons left,
SI DCN right, SI Pons right).
SI ratio DCN-to-pons showed no significant differences between left and right hemisphere
(observer 1 (p = 0.390), observer 2 (p = 0.722)). SI ratio DCN-to-pons at the right hemisphere
was measured in median with 0.997 (0.860–1.072) for observer 1 and 0.991 (0.887–1.071) for
observer 2, and at the left hemisphere with 0.999 (0.906–1.111)) for observer 1 and 0.989
(0.884–1.089) for observer 2. (Table 4)
SI ratio differences between the first and the last MRI examination of the patients showed
no significant differences, whether at the left nor at the right hemisphere (observer 1
(p = 0.831), observer 2 (p = 0.163)). SI ratio differences between the first and the last MRI
examination of the patients was measured at the right hemisphere in median with -0.011
(-0.125–0.069) for observer 1 and -0.021 (-0.100–0.043) for observer 2, and at the left hemi-
sphere with -0.002 (-0.079–0.138) for observer 1 and -0.010 (-0.096–0.082) for observer 2.
(Table 1) Based on a one-sample t-test, the first and the last MRI examination was tested to be
significant different from 0. For both observers, no significant difference from 0 was found
(observer 1: p = 0.896/0.402; observer 2: p = 0.451/0.098 [left/right]).
LA-ICP-MS data
Visual assessment of LA-ICP-MS analysis as well as a quantitative analysis was performed with
a limit of quantification (LOQ) of 220 ng gadolinium/g tissue and a limit of detection (LOD)
of 67 ng/g. Gadolinium concentrations in the DCN of the research beagle dog could be deter-
mined between 1.5 to 2.5 μg gadolinium/g tissue, 35 months after last gadodiamide injection.
In agreement with the visual assessment of the DCN, gadolinium levels were higher in the
DCN than in the surrounding area of the DCN. A co-localisation of Gd and zinc (Zn) was
detectable, both increasingly detectable in vessels, especially at the DCN. Furthermore, an
anti-correlation with phosphorus (P) was detectable, which is visible in μXRF and LA-ICP-MS.
The results are summarized in Fig 2.
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Table 2. SI ratio differences.









































1 125.053 126.691 0.987 124.613 125.208 0.995 124.606 126.761 0.983 125.667 125.343 1.003
1 277.428 281.183 0.987 280.295 287.391 0.975 0.000 -0.020 272.885 282.305 0.967 279.496 285.953 0.977 -0.016 -0.025
2 366.1 372.94 0.982 355.652 361.514 0.984 471.703 468.736 1.006 460.095 466.525 0.986
2 362.487 359.643 1.008 360.836 355.127 1.016 0.026 0.032 362.179 360.978 1.003 357.583 361.620 0.989 -0.003 0.003
3 172.257 173.655 0.992 174.972 176.618 0.991 173.935 176.551 0.985 176.775 177.906 0.994
3 178.492 183.944 0.970 179.350 184.430 0.972 -0.022 -0.018 179.023 183.55 0.975 175.918 186.732 0.942 -0.010 -0.052
3 422.66 449.613 0.940 437.129 459.989 0.950 -0.052 -0.040 419.148 455.787 0.920 429.200 458.764 0.936 -0.066 -0.058
4 175.919 172.502 1.020 172.275 175.804 0.980 172.698 175.878 0.982 173.125 175.544 0.986
4 343.066 340.951 1.006 344.929 346.556 0.995 -0.014 0.015 349.659 342.713 1.020 350.028 348.415 1.005 0.038 0.018
5 614.737 628.453 0.978 639.614 647.677 0.988 622.014 632.662 0.983 634.766 652.891 0.972
5 643.488 642.776 1.001 647.769 635.415 1.019 0.023 0.032 648.4 653.633 0.992 650.581 640.549 1.016 0.009 0.043
6 423.872 427.325 0.992 430.475 429.126 1.003 430.852 439.226 0.981 431.025 431.684 0.998
6 1337.617 1308.215 1.022 1350.109 1308.886 1.031 0.031 0.028 1345.156 1341.79 1.003 1347.488 1345.814 1.001 0.022 0.003
7 997.558 993.47 1.004 995.635 1003.037 0.993 988.921 1000.341 0.989 998.839 1004.823 0.994
7 590.895 589.339 1.003 580.894 577.059 1.007 -0.001 0.014 581.192 591.546 0.982 572.667 593.458 0.965 -0.006 -0.029
8 121.255 124.544 0.974 122.963 116.500 1.055 122.184 124.16 0.984 122.953 117.417 1.047
8 149.632 134.637 1.111 129.449 129.388 1.000 0.138 -0.055 148.141 138.991 1.066 126.260 128.084 0.986 0.082 -0.061
9 97.817 88.727 1.102 95.320 90.399 1.054 98.402 90.347 1.089 95.379 90.695 1.052
9 97.977 95.76 1.023 97.402 95.758 1.017 -0.079 -0.037 97.07 95.184 1.020 97.455 95.400 1.022 -0.069 -0.030
10 131.948 133.301 0.990 130.471 136.535 0.956 128 134.089 0.955 130.690 137.105 0.953
10 120.822 125.631 0.962 121.811 123.667 0.985 -0.028 0.029 112.01 122.136 0.917 110.887 122.901 0.902 -0.037 -0.051
11 133.753 134.268 0.996 134.603 134.671 0.999 134.295 133.571 1.005 136.521 136.333 1.001
11 129.713 124.613 1.041 129.773 121.503 1.068 0.045 0.069 130.938 126.121 1.038 127.061 122.018 1.041 0.033 0.040
12 76.143 78.517 0.970 77.633 78.761 0.986 73.75 78.213 0.943 76.652 79.258 0.967
12 86.485 95.423 0.906 85.735 99.646 0.860 -0.063 -0.125 84.317 95.434 0.884 85.253 96.134 0.887 -0.059 -0.080
13 707.581 726.456 0.974 690.724 692.353 0.998 713.182 735.14 0.970 695.767 704.060 0.988
13 626.935 637.184 0.984 611.346 622.576 0.982 0.010 -0.016 615.634 624.683 0.986 629.760 611.041 1.031 0.015 0.042
14 504.183 517.667 0.974 514.801 519.431 0.991 509.696 522.529 0.975 517.467 513.294 1.008
14 136.327 138.181 0.987 137.012 139.957 0.979 0.013 -0.012 136.547 138.476 0.986 136.415 138.630 0.984 0.011 -0.024
15 101.85 96.083 1.060 101.685 94.867 1.072 103.259 96.485 1.070 103.662 96.792 1.071
15 123.488 124.719 0.990 124.653 123.724 1.008 -0.070 -0.064 125.277 123.168 1.017 125.057 127.250 0.983 -0.053 -0.088
15 662.897 672.978 0.985 662.978 672.459 0.986 -0.075 -0.086 659.586 677.183 0.974 660.568 680.373 0.971 -0.096 -0.100
median 0.990 0.994 -0.001 -0.016 0.985 0.989 -0.006 -0.029
min 0.906 0.860 -0.079 -0.125 0.884 0.887 -0.096 -0.100
max 1.111 1.072 0.138 0.069 1.089 1.071 0.082 0.043











































































The current restrospective clinical study is the first study observing multiple gadodiamide
applications in veterinary patients in a clinical set-up. The background of this study was the
ongoing debate about the clinical relevance of hyperintensities of the DCN after multiple
GBCA applications in humans. The hypothesis of this study was that there is a detectable
increased hyperintensity on non-enhanced T1 weighted sequences in the DCN of dogs after
multiple gadodiamide administrations and a measurable gadolinium retention in the cerebel-
lum of dogs after chemical analysis based on LA-ICP-MS. The hypothesis has to be partially
rejected.
This study showed 1) no hyperintensities on non-enhanced T1 weighted sequences in the
clinical dog patients and 2) a Gd concentration of 1.5 to 2.5 μg gadolinium/g tissue in the
brain of a research beagle dog 35 months after last gadodiamide injection.
Table 4. Intraclass-correlation coefficient (ICC).
ICC confidence interval
measurement hemisphere mean min max
SI DCN left 0.999 0.998 0.999
SI Pons 0.999 0.998 1.000
SI ratio 0.994 0.989 0.999
SI ratio difference 0.949 0.847 0.983
SI DCN right 0.999 0.998 1.000
SI Pons 0.999 0.998 0.999
SI ratio 0.910 0.811 0.957
SI ratio difference 0.863 0.592 0.954
Intraclass-correlation coefficient (ICC) between observer 1 and 2. Displayed as mean and confidence interval for SI
measurements at the DCN and Pons, for SI ratios and SI ratio differences in the left and right hemisphere
https://doi.org/10.1371/journal.pone.0227649.t004
Table 3. Measurement data.
observer 1 observer 2 Mann-
Whitney U
test









SI DCN left 30 76 1338 358 307 74 1345 361 308 0.988
SI Pons left 30 79 1308 360 306 78 1342 366 311 0.882
SI ratio left 30 0.906 1.111 0.999 0.041 0.862 0.884 1.089 0.989 0.043 0.158 0.329
SI DCN right 30 78 1350 358 308 77 1347 361 310 0.976
SI Pons right 30 79 1309 359 305 79 1346 365 311 0.894
SI ratio right 30 0.860 1.072 0.997 0.039 0.701 0.887 1.071 0.991 0.040 0.227 0.605
SI ratio difference
left
15 -0.079 0.138 -0.002 0.055 0.896 -0.096 0.082 -0.010 0.048 0.451 0.756
SI ratio difference
right
15 -0.125 0.069 -0.011 0.051 0.402 -0.100 0.043 -0.021 0.045 0.098 0.548
Measurements of observer 1 and 2 displayed as mean, min, max and SD for DCN and Pons, SI ratio and SI ratio difference in the left and right hemisphere. One-sample
t-test for both hemispheres, testing for differences from 1 (for SI ratios), respective from 0 (SI ratio differences). Additional p- values of the Mann-Whitney-U test
comparing results of oberserver 1 and 2.
https://doi.org/10.1371/journal.pone.0227649.t003
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With these findings, our study supports the hypothesis that a specific threshold is needed to
identify hyperintensities on unenhanced T1-weighted images. It seems likely that the data of
this dog patient population was not exposed to gadodiamide in an amount to exceed this
threshold. With a median cumulative dose of 6.83 mmol/animal (range 0.54 to 16.65mmol/
animal) the clinical dataset shows much less cumulative GBCA dose as compared to published
reports from human medicine [1] or animal experiments.[53] Even if a superior brain clear-
ance of macrocyclic GBCAs over linear GBCAs is described[54, 55] and all dogs of this study
got a linear GBCA administration, the cumulative dose did not reach a visible level of hyperin-
tensities after 2–3 administrations. We determined mean SI ratio differences between first and
last MRI examination between 0.2% and 6.9% (range -12.5% to 13.8%), which was not signifi-
cantly different from 0. (Table 1) This is much lower than in the study of Hu et al., were an SI
increase between first and most recent MRI examination with an increase of 18.6% ± 12.7%
(range 0.5% to 47.5%) for the DCN was reported.[14] In the study of Hu et al., human patients
received a significant number of subsequent GBCA examinations, ranging between 5 and 37.
Weberling et al. described a significant SI increase in the DCN after at least 5 consecutive
GBCA injections of gadobenate dimeglumine.[13]
Although the retrospective MRI study did not indicate any visible effect of SI increase after
multiple gadodiamide exposures, further studies based on LA-ICP-MS showed that the optical
threshold was not reached for a potential visible effect. Most of the dog patients in this study
had a history of neoplastic or neurological disease as reason for MRI examination (Table 1). In
the patient records of the dogs, no side effects were linked with the contrast media application.
This result is of clinical relevance for all current and future patients in veterinary medicine,
which have a history of diagnosed brain tumors (such as meningiomas gliomas, nerve sheeth
tumors, pituitary adenomas) or meningoencephalitis. Recurrent MRI examination are of
interest in veterinary medicine mainly in dog patients after radiation therapy for follow ups
and/or recidive pathologies. Our dataset showed that mostly not more than two MRI examina-
tions with GBCA are performed during clinical work-up in veterinary medicine. This is a clear
Fig 2. Representative results for the LA-ICP-MS analyses of two cryo cerebellum samples of one dog treated with gadodiamide 35 months before euthanasia.
Anatomy is shown on histological and μXRF images. LA-ICP-MS results are displayed as quantitative distribution map of gadolinium (158Gd) and as qualitative
distribution maps of phosphorus (31P), iron (57Fe) and zinc (66Zn). LA-ICP-MS analyses were performed with a laser spot size of 10 μm and a limit of detection at 67 ng/
g (LOD). A clear colocalization of gadolinium and zinc displays in both samples.
https://doi.org/10.1371/journal.pone.0227649.g002
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difference in comparison with human medicine, were more than 35 linear GBCA administra-
tions to a single patient are reported.[18]
Even if there is no clinically visible hyperintensity on unenhanced T1-weighted MR images,
this does not mean there is no deposition of gadolinium through gadodiamide application
after multiple contrast media administrations in dogs. From human medicine it is known that
approximately 6 injections of linear GBCAs are needed, before hyperintensities in the DCN
become detectable on MRI[7, 56] On the other hand, gadolinium deposition was detectable
after a single injection of linear GBCAs based on LA-ICP-MS measurments in the brain of
sheep.[25] This study confirms gadolinium detection in the brain of a research beagle dog
based on the chemical analysis of the Gd content. After three examinations, two times with
1x0.1 mmol/kg and once with 3x0.05 mmol/kg gadodiamide, Gd was measurable 35 month
after the last administration. Accordingly, it could be shown in this study that the described
Gd deposition in the brain of different species similarly occurs in dogs. Therefore, our findings
support the hypothesis of irreversible or long lasting Gd deposition at the DCN. The current
explanation about the pathomechanism is based on de-chelation effects of linear GBCA and
transmetalation in co-localization with other elements, such as Fe, Co, Cu, Zn.[25, 57] We
could show similar effects in the research beagle dog, which supports the ongoing discussion.
As dogs are a widely used species for translational medicine and model for lots of pre-clinical
studies during the approval of new medical products for human medicine, the results of our
study should be recognized for all translational studies in future.
Even if the pathomechanism is not clarified at the moment and there are ongoing studies
about differences between linear and macrocyclic GBCAs, from a scientific and ethical point
of view it is mandatory to reduce the GBCA administration to the essential number with diag-
nostic importance for the patients. At the same time it is important to maintain the benefit of
GBCA as long as there are no valuable alternative contrast media available. This should be
done with respect to the risk of Gd deposition and its accumulation during recurrent contrast
agent administrations.
As one of the limitations of this study, we have to mention that the number of patients and
the number of gadodiamide administrations was lower than in comparable restrospective
human studies. The reason is that in veterinary medicine dogs, as the most used private owned
species, will not be imaged more often in MRI. This can be explained by the costs (payed by
the owner) and the shorter life-span of a dog in comparison to humans. As our data reflects
the daily business in a large university hospital, this was the maximum available data, which
provides a relevant veterinary insight into this topic. Unfortunately, we did not have an MRI
of the research beagle dogs brain, who had multiple gadodiamide administrations before
euthanasia. This was caused by the fact that the brain of the dog was used as an add-on to
another unrelated study which focused on other regions than the animals brain during MRI
examination. It is a beneficial circumstance to have the results of the chemical analysis from
this dog, even if there is no associated MRI of the brain. Based on the gained knowledge that
an increased signal intensity of the brain might only be visible when the number of GBCA
injections surpasses a certain threshold[34], it may have been questionable if this threshold
would have been exceeded or not. According to the current knowledge, gadolinium first
becomes visible in MRI if a threshold of approximately 1 μg gadolinium/g tissue is exceeded.
[25] We assessed between 1.5 to 2.5 μg gadolinium/g tissue in the DCN of the research beagle
dog, which would have caused a signal intensity change in MRI. Currently published case
reports and research studies describe LA-ICP-MS as a useful tool to measure the quantities of
retained gadolinium in human[19, 58, 59] and rodent tissues[47, 60]. Potential risk factors
with effect on Gd retention described are ongoing neuroinflammation[60] or primary gliomas
[59]. Additionally, any type of inflammation can negatively influence the blood brain barrier
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permeability[61] and therefore could be potential risk factor for gadolinium retention. In this
study LA-ICP-MS was performed in the brain of a healthy research beagle dog, which was con-
sidered to be not influenced by clinical factors. On the other side the dataset of this study
includes patients showing exactly such types of diseases with potential effect on gadolinium
retention. The question how and in which quantity the underlying diseases or a reduced
blood-brain-barrier influenced the gadolinium retention in the brain can not be estimated and
has to be evaluated in further studies.
Another potential confounding factor for all clinical studies is the time between last GBCA
administration and the MRI examination to detect hyperintensities in the DCN or until
LA-ICP-MS measurement of gadolinium, as this time is crucial to differentiate between the
soluble and insoluble form of gadolinium. In this study the median number of days between
last GBCA application and MRI examination was 136 (range 24 to 582days). Accordingly
there was enough gadolinium-free-time to detect insoluble gadolinium deposits only.
In conclusion, we could show that no hyperintensities on non-enhanced T1 weighted
sequences in the clinical dog patients after 2–3 gadodiamide administrations of 0.1 mmol/kg
were detactable and that between 1.5 to 2.5 μg gadolinium/g tissue could be determined in the
brain of a research beagle dog 35 months after his last gadodiamide injection. The importance
and clinical relevance of gadolinium retention of subvisible contents, the pathomechanism
and the potential side effects based on Gd deposition still requires further investigation.
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